Pharmacogenetics for genes associated with age-related macular degeneration in the Comparison of AMD Treatments Trials (CATT)
about
Anti-vascular endothelial growth factor for neovascular age-related macular degenerationGenetics and age-related macular degeneration: a practical review for the clinicianManagement of neovascular age-related macular degeneration: current state-of-the-art care for optimizing visual outcomes and therapies in developmentDefining response to anti-VEGF therapies in neovascular AMDAdvances in the genomics of common eye diseasesHIGH-DOSE HIGH-FREQUENCY AFLIBERCEPT FOR RECALCITRANT NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.Association between polymorphism rs11200638 in the HTRA1 gene and the response to anti-VEGF treatment of exudative AMD: a meta-analysis.Endothelial PAS domain-containing protein 1 (EPAS1) gene polymorphisms and response to anti-VEGF therapy in the comparison of AMD treatments trials (CATT).VEGFA and VEGFR2 gene polymorphisms and response to anti-vascular endothelial growth factor therapy: comparison of age-related macular degeneration treatments trials (CATT).Clinical applications of age-related macular degeneration genetics.Flicker-induced retinal vasodilatation is not dependent on complement factor H polymorphism in healthy young subjectsNo clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38Incidence of choroidal neovascularization in the fellow eye in the comparison of age-related macular degeneration treatments trials.Pharmacogenetic associations with long-term response to anti-vascular endothelial growth factor treatment in neovascular AMD patientsRisk of geographic atrophy in the comparison of age-related macular degeneration treatments trials.Growth of geographic atrophy in the comparison of age-related macular degeneration treatments trials.Vision from next generation sequencing: multi-dimensional genome-wide analysis for producing gene regulatory networks underlying retinal development, aging and diseaseBevacizumab treatment for neovascular age-related macular degeneration in the setting of a clinic: "real life" long-term outcomeAssociation of Baseline Characteristics and Early Vision Response with 2-Year Vision Outcomes in the Comparison of AMD Treatments Trials (CATT)VEGFR2 Gene Polymorphisms and Response to Anti-Vascular Endothelial Growth Factor Therapy in Age-Related Macular Degeneration.A Validated Phenotyping Algorithm for Genetic Association Studies in Age-related Macular Degeneration.Single-Nucleotide Polymorphisms Associated With Age-Related Macular Degeneration and Lesion Phenotypes in the Comparison of Age-Related Macular Degeneration Treatments Trials.Incidence and Growth of Geographic Atrophy during 5 Years of Comparison of Age-Related Macular Degeneration Treatments Trials.Inflammatory Cytokines Induce Expression of Chemokines by Human Retinal Cells: Role in Chemokine Receptor Mediated Age-related Macular DegenerationHigher plasma levels of complement C3a, C4a and C5a increase the risk of subretinal fibrosis in neovascular age-related macular degeneration: Complement activation in AMD.Targeting the complement system for the management of retinal inflammatory and degenerative diseases.Immunology of age-related macular degenerationThe role of the complement system in age-related macular degeneration.How genetic studies have advanced our understanding of age-related macular degeneration and their impact on patient care: a review.Association between variants A69S in ARMS2 gene and response to treatment of exudative AMD: a meta-analysis.Pharmacogenetics and nutritional supplementation in age-related macular degeneration.Complement pathway biomarkers and age-related macular degeneration.Association of the polymorphism Y402H in the CFH gene with response to anti-VEGF treatment in age-related macular degeneration: a systematic review and meta-analysis.Risk factors and biomarkers of age-related macular degeneration.CFH Y402H polymorphism and response to intravitreal ranibizumab in Brazilian patients with neovascular age-related macular degeneration.A prospective multicenter study on genome wide associations to ranibizumab treatment outcome for age-related macular degeneration.Pharmacogenetics of Complement Factor H Y402H Polymorphism and Treatment of Neovascular AMD with Anti-VEGF Agents: A Meta-Analysis.Incidence and risk factors of retreatment after three-monthly aflibercept therapy for exudative age-related macular degeneration.ARMS2 A69S polymorphism is associated with the number of ranibizumab injections needed for exudative age-related macular degeneration in a pro re nata regimen during 4 years of follow-up.Pharmacogenetic labyrinth of neovascular age-related macular degeneration therapy: how to escape and move forward?
P2860
Q24194251-CC1E5048-8A9A-47D1-887F-882ECD6978F8Q26738526-787597F5-518F-4E00-8952-D773D7AC0546Q26824335-43009997-7AA6-4EEF-B359-4409F2CE5E37Q26996510-C65507D5-8BF8-4921-B61B-BA2842726D59Q27008236-20299F7A-E1B7-4E15-99F1-E04548CFC602Q30491978-0400F9E3-BE4D-4567-A48F-5C468B9ED42DQ33823849-F542AEF8-847A-4D41-A7D9-78049A2859C0Q34005587-AF6DFAAE-15A2-4BB8-93B1-F7CBA4BEA4D9Q34170457-F527F41C-745F-4271-A3B0-3CFF9B8DD7A6Q34355357-E2A0303A-5C1F-4BDD-A635-4F7001C31A55Q34477472-22878D1B-92D5-4D6A-8E9A-A6FE822825E2Q34620551-E5FDF48B-E10C-4050-AC8D-1651377A7440Q34740219-AB9A78CD-B447-4C19-AA64-BBF65C875EF0Q34781693-3EEBF2DD-B77E-4D48-B283-92E043EB7095Q35003936-E1F4EEE5-F0FF-49CB-876D-C5C129254F7CQ35214092-36D7EC27-571E-487D-B219-F56D2C743B6CQ35470460-F990BECB-298A-4268-9AC7-A9AD98CCD16FQ35503206-1FFF6C79-C0E3-4333-83DC-8A01EB4A2996Q35780510-9110FF06-81EC-47D4-9386-A53A346768D4Q35893840-5FC52516-54B4-4905-96B0-4AF720A0ED03Q35932943-EA4F4EA5-2EBD-4684-8BB6-3D4C87EECA37Q35995626-E139CB4A-B20E-4671-80C5-223C738E874DQ36247080-3BC1118B-E2AE-4B61-B5AE-6D136E0F4D33Q36314850-9D437870-0214-417B-B1E8-1B350FF5F2B0Q36583714-FCB7C87C-4AD4-493A-A57C-A2F75D506987Q37262287-E55DC5A8-D4D7-4B3E-AA94-E2C51AD44BDDQ37614752-B1E78F4A-39E4-4A8A-84A5-F82A45BCBA67Q37646779-6025B2C3-A59B-4532-965D-BDE80C910A92Q38151224-C6CBCE30-27A7-47F8-9D11-105FFE24E849Q38245807-D0905863-B497-45CA-9597-AB4BA6C71DD4Q38510019-1854BF7E-4771-4514-9CEB-2D436AC9C49DQ38614012-BFC63A7E-849B-4CD4-873A-B36BA3B03FB1Q38827325-6C604C68-A0B0-4B61-89DE-0F591B3635B7Q38828895-4CCB41B0-EAA5-4E92-B3F1-4C1F52B3A588Q41289450-82D69F8B-B3B2-4CFD-A1E4-3C79DF7F6129Q41504310-6C45120D-8602-4ACE-8AE5-5CE124758E23Q41833477-7CE8FF17-579D-4A52-8F02-EEA0BCBFA78EQ42136459-DBF10215-D809-402C-A3BA-939BAC8D07FDQ43364243-879B118B-D5B6-42C7-8908-3612F3B9DF3FQ44097181-2820DBEE-EC2D-4431-8931-D8E7B74FC259
P2860
Pharmacogenetics for genes associated with age-related macular degeneration in the Comparison of AMD Treatments Trials (CATT)
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Pharmacogenetics for genes ass ...... f AMD Treatments Trials (CATT)
@ast
Pharmacogenetics for genes ass ...... f AMD Treatments Trials (CATT)
@en
Pharmacogenetics for genes ass ...... rison of AMD Treatments Trials
@nl
type
label
Pharmacogenetics for genes ass ...... f AMD Treatments Trials (CATT)
@ast
Pharmacogenetics for genes ass ...... f AMD Treatments Trials (CATT)
@en
Pharmacogenetics for genes ass ...... rison of AMD Treatments Trials
@nl
prefLabel
Pharmacogenetics for genes ass ...... f AMD Treatments Trials (CATT)
@ast
Pharmacogenetics for genes ass ...... f AMD Treatments Trials (CATT)
@en
Pharmacogenetics for genes ass ...... rison of AMD Treatments Trials
@nl
P2093
P2860
P1433
P1476
Pharmacogenetics for genes ass ...... f AMD Treatments Trials (CATT)
@en
P2093
Comparison of AMD Treatments Trials Research Group
Daniel F Martin
David G Callanan
Gayle J T Pauer
Gui-Shuang Ying
Gwen M Sturgill-Short
Ivana K Kim
Jiayan Huang
Maureen G Maguire
Michael L Klein
P2860
P304
P356
10.1016/J.OPHTHA.2012.11.037
P577
2013-01-18T00:00:00Z